vs
拜玛林制药（BMRN）与monday.com Ltd.（MNDY）财务数据对比。点击上方公司名可切换其他公司
拜玛林制药的季度营收约是monday.com Ltd.的1.2倍（$874.6M vs $704.0M），monday.com Ltd.净利率更高（1.3% vs -5.3%，领先6.7%），monday.com Ltd.自由现金流更多（$224.6M vs $58.9M）
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
monday.com是总部位于以色列特拉维夫的云平台服务商，2014年正式推出核心产品，支持用户自定义搭建应用及项目管理工具。公司2019年完成1.5亿美元融资，估值达19亿美元，2021年6月正式公开上市。
BMRN vs MNDY — 直观对比
营收规模更大
BMRN
是对方的1.2倍
$704.0M
净利率更高
MNDY
高出6.7%
-5.3%
自由现金流更多
MNDY
多$165.7M
$58.9M
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $874.6M | $704.0M |
| 净利润 | $-46.6M | $9.4M |
| 毛利率 | 68.5% | 89.6% |
| 营业利润率 | -5.1% | -4.4% |
| 净利率 | -5.3% | 1.3% |
| 营收同比 | 17.0% | — |
| 净利润同比 | -137.3% | — |
| 每股收益（稀释后） | $-0.22 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRNMNDY
| Q4 25 | $874.6M | — | ||
| Q3 25 | $776.1M | $704.0M | ||
| Q2 25 | $825.4M | $453.0M | ||
| Q1 25 | $745.1M | $216.9M | ||
| Q4 24 | $747.3M | — | ||
| Q3 24 | $745.7M | $527.1M | ||
| Q2 24 | $712.0M | $337.9M | ||
| Q1 24 | $648.8M | $162.3M |
净利润BMRNMNDY
| Q4 25 | $-46.6M | — | ||
| Q3 25 | $-30.7M | $9.4M | ||
| Q2 25 | $240.5M | $21.4M | ||
| Q1 25 | $185.7M | $7.1M | ||
| Q4 24 | $124.9M | — | ||
| Q3 24 | $106.1M | $-14.2M | ||
| Q2 24 | $107.2M | $-21.7M | ||
| Q1 24 | $88.7M | $-14.7M |
毛利率BMRNMNDY
| Q4 25 | 68.5% | — | ||
| Q3 25 | 82.0% | 89.6% | ||
| Q2 25 | 81.8% | 89.6% | ||
| Q1 25 | 79.7% | 89.2% | ||
| Q4 24 | 81.8% | — | ||
| Q3 24 | 74.7% | 89.0% | ||
| Q2 24 | 81.7% | 89.2% | ||
| Q1 24 | 80.7% | 89.5% |
营业利润率BMRNMNDY
| Q4 25 | -5.1% | — | ||
| Q3 25 | -6.0% | -4.4% | ||
| Q2 25 | 33.5% | -0.7% | ||
| Q1 25 | 30.0% | -2.3% | ||
| Q4 24 | 21.6% | — | ||
| Q3 24 | 15.3% | -7.1% | ||
| Q2 24 | 16.9% | -10.3% | ||
| Q1 24 | 13.6% | -14.0% |
净利率BMRNMNDY
| Q4 25 | -5.3% | — | ||
| Q3 25 | -4.0% | 1.3% | ||
| Q2 25 | 29.1% | 4.7% | ||
| Q1 25 | 24.9% | 3.3% | ||
| Q4 24 | 16.7% | — | ||
| Q3 24 | 14.2% | -2.7% | ||
| Q2 24 | 15.1% | -6.4% | ||
| Q1 24 | 13.7% | -9.0% |
每股收益（稀释后）BMRNMNDY
| Q4 25 | $-0.22 | — | ||
| Q3 25 | $-0.16 | — | ||
| Q2 25 | $1.23 | — | ||
| Q1 25 | $0.95 | — | ||
| Q4 24 | $0.65 | — | ||
| Q3 24 | $0.55 | — | ||
| Q2 24 | $0.55 | — | ||
| Q1 24 | $0.46 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $6.1B | $1.0B |
| 总资产 | $7.6B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BMRNMNDY
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.2B | $1.7B | ||
| Q1 25 | $1.0B | $1.4B | ||
| Q4 24 | $942.8M | — | ||
| Q3 24 | $675.4M | $1.1B | ||
| Q2 24 | $972.1M | $1.3B | ||
| Q1 24 | $747.0M | $1.1B |
股东权益BMRNMNDY
| Q4 25 | $6.1B | — | ||
| Q3 25 | $6.1B | $1.0B | ||
| Q2 25 | $6.0B | $1.2B | ||
| Q1 25 | $5.8B | $1.0B | ||
| Q4 24 | $5.7B | — | ||
| Q3 24 | $5.4B | $813.5M | ||
| Q2 24 | $5.3B | $910.1M | ||
| Q1 24 | $5.1B | $813.5M |
总资产BMRNMNDY
| Q4 25 | $7.6B | — | ||
| Q3 25 | $7.6B | $1.7B | ||
| Q2 25 | $7.5B | $2.0B | ||
| Q1 25 | $7.1B | $1.7B | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | $6.9B | $1.3B | ||
| Q2 24 | $7.1B | $1.5B | ||
| Q1 24 | $6.9B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.6M | $234.4M |
| 自由现金流经营现金流 - 资本支出 | $58.9M | $224.6M |
| 自由现金流率自由现金流/营收 | 6.7% | 31.9% |
| 资本支出强度资本支出/营收 | 4.7% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 25.02× |
| 过去12个月自由现金流最近4个季度 | $725.0M | $608.3M |
8季度趋势，按日历期对齐
经营现金流BMRNMNDY
| Q4 25 | $99.6M | — | ||
| Q3 25 | $368.7M | $234.4M | ||
| Q2 25 | $185.3M | $147.7M | ||
| Q1 25 | $174.4M | $92.0M | ||
| Q4 24 | $185.6M | — | ||
| Q3 24 | $221.5M | $156.9M | ||
| Q2 24 | $118.8M | $90.3M | ||
| Q1 24 | $47.0M | $42.7M |
自由现金流BMRNMNDY
| Q4 25 | $58.9M | — | ||
| Q3 25 | $340.2M | $224.6M | ||
| Q2 25 | $168.2M | $141.8M | ||
| Q1 25 | $157.6M | $90.5M | ||
| Q4 24 | $166.1M | — | ||
| Q3 24 | $203.0M | $151.4M | ||
| Q2 24 | $97.4M | $85.6M | ||
| Q1 24 | $20.9M | $39.2M |
自由现金流率BMRNMNDY
| Q4 25 | 6.7% | — | ||
| Q3 25 | 43.8% | 31.9% | ||
| Q2 25 | 20.4% | 31.3% | ||
| Q1 25 | 21.2% | 41.7% | ||
| Q4 24 | 22.2% | — | ||
| Q3 24 | 27.2% | 28.7% | ||
| Q2 24 | 13.7% | 25.3% | ||
| Q1 24 | 3.2% | 24.1% |
资本支出强度BMRNMNDY
| Q4 25 | 4.7% | — | ||
| Q3 25 | 3.7% | 1.4% | ||
| Q2 25 | 2.1% | 1.3% | ||
| Q1 25 | 2.3% | 0.7% | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 2.5% | 1.0% | ||
| Q2 24 | 3.0% | 1.4% | ||
| Q1 24 | 4.0% | 2.2% |
现金转化率BMRNMNDY
| Q4 25 | — | — | ||
| Q3 25 | — | 25.02× | ||
| Q2 25 | 0.77× | 6.91× | ||
| Q1 25 | 0.94× | 12.99× | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 2.09× | — | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 0.53× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
MNDY
暂无分部数据
